BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022.
If You Had Invested Your 2013 Rent in Dogecoin, You Could Now Own This California Mansion With 4 Beds And 5 Baths
Rent prices in the United States have been steadily climbing, making it increasingly challenging for tenants to find affordable housing.
